Invivyd (IVVD) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lyell Immunopharma (LYEL) has outperformed Invivyd (IVVD) over the past year, losing 51.9% versus a loss of 57.3%. Over five years, LYEL leads with a -96.7% price change compared with -97.8% for IVVD. Lyell Immunopharma is the larger company by market cap ($215.2 million vs $204.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | LYEL |
|---|---|---|
| Share price | $0.6925 | $8.78 |
| Market cap | $204.12M | $215.16M |
| 1-day change | -1.13% | -0.11% |
| YTD return | -71.64% | -71.44% |
| 1-year return | -57.29% | -51.86% |
| 5-year return | -97.84% | -96.69% |
| EPS (TTM) | $-0.33 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $45.00 |
| 52-week low | $0.528 | $8.21 |
| Distance from 52-week high | -77.44% | -80.49% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1344.04% | +331.44% |
| Average volume | 4.90M | 145.70K |
| Shares outstanding | 294.76M | 24.51M |
| Employees | 122 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
IVVD vs LYEL FAQ
Which is bigger, Invivyd or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $215.16M compared with $204.12M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or LYEL?
LYEL returned -51.86% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Lyell Immunopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Invivyd and Biotechnology: Pharmaceutical Preparations for Lyell Immunopharma.